Mr. Weinberg is an experienced commercial executive in the field of cancer molecular diagnostics and recognized leader in the disciplines of commercial infrastructure build-out, third party reimbursement and assay pipeline management.  He has managed successful development efforts at numerous early-stage companies across multiple platforms and cancer disease types. Most recently, he led the commercial launch of the Theralink Assay for Breast Cancer™ for Theralink Technologies (OTC: THER). Prior to Theralink, Mr. Weinberg launched the GEM ExTra™ Cancer Panel for Ashion Analytics, a TGen® Clinical Lab. Based on this successful market introduction, Ashion was acquired by Exact Sciences (NASDAQ: EXAS) in February of 2021.

In prior early-commercial leadership roles at Natera (NSDQ: NTRA), Guardant Health (NADQ: GH), Biodesix (NSDQ:BDSX) and Genomic Health(NADQ: GHI – EXAS), Mr. Weinberg participated in and led the development of first-in-class oncology molecular assays, the achievement of record early adoption and the initiation of first-time payor policies for these innovative cancer molecular tools. Mr. Weinberg is a US Army veteran, cancer survivor, and has served on the Board of Directors for the Lymphoma Research Foundation [LRF]. He holds a bachelor’s degree from Siena College and master’s in public administration from Marist College.